Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
View Patent ↗Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
1. A method for reducing the humoral immune response in a subject comprising the step of
administering a pharmaceutical composition which comprises a therapeutically effective amount of a LT-β-R blocking agent selected from the group consisting of: a soluble lymphotoxin-β receptor, an antibody directed against LT-β receptor, and an antibody directed against surface LT ligand to a subject that would benefit from a reduced humoral response, such that a reduced humoral response occurs in the subject.
2. The method according to claim 1 , wherein the LT-β-R blocking agent comprises a soluble lymphotoxin-β receptor having a ligand binding domain that can selectively bind to a surface LT ligand.
3. The method according to claim 2 , wherein the soluble lymphotoxin-β receptor comprises a human immunoglobulin Fc domain.
4. The method of claim 1 , wherein the LT-β-R blocking agent further comprises a pharmaceutically acceptable carrier or adjuvant.
5. A method for reducing the association of immune complexes and B cell follicles in a subject comprising administering an amount of an LT-β-R blocking agent selected from the group consisting of: a soluble lymphotoxin-β receptor, an antibody directed against LT-β receptor, and an antibody directed against surface LT ligand to a subject that would benefit from a reduced association of immune complexes and B cell follicles, such that a reduced association of immune complexes and B cell follicles occurs in the subject.
6. The method of claim 5 wherein the LT-β-R blocking agent comprises a soluble LT-β-R having a ligand binding domain that can selectively bind to a surface LT ligand.
7. The method of claim 6 , wherein said soluble LT-β-R comprises a human immunoglobulin Fc domain.
8. The method of claim 1 , wherein the subject is suffering from an autoimmune disorder.
9. The method of claim 2 , wherein the subject is suffering from an autoimmune disorder.
10. The method of claim 5 , wherein the subject is suffering from an autoimmune disorder.
11. The method of claim 6 , wherein the subject is suffering from an autoimmune disorder.
12. The method of claim 1 , wherein the presentation of antigen on follicular dendritic cells (FDCs) in the subject is reduced.
13. The method of claim 2 , wherein the presentation of antigen on follicular dendritic cells (FDCs) in the subject is reduced.
14. The method of claim 5 , wherein the presentation of antigen on follicular dendritic cells (FDCs) in the subject is reduced.
15. The method of claim 6 , wherein the presentation of antigen on follicular dendritic cells (FDCs) in the subject is reduced.
16. The method of claim 12 , wherein said reduction of the presentation of antigen on FDCs results in a reduction of the immune response in the subject.
17. The method of claim 16 , wherein the blocking agent is administered to the subject prior to the introduction of the antigen into the subject, such that the presentation of antigen on FDCs is reduced, thereby reducing the immune response in the subject.
18. The method of claim 16 , wherein the blocking agent is administered to the subject after association of the FDCs with the antigen, and wherein said blocking agent disrupts the association of the FDCs with the antigen, thereby reducing the immune response in the subject.
19. The method of claim 13 , wherein said reduction of the presentation of antigen on FDCs results in a reduction of the immune response in the subject.
20. The method of claim 19 , wherein the blocking agent is administered to the subject prior to the introduction of the antigen into the subject, such that the presentation of antigen on FDCs is reduced, thereby reducing the immune response in the subject.
21. The method of claim 19 , and wherein the blocking agent is administered to the subject after association of the FDCs with the antigen, wherein said blocking agent disrupts the association of the FDCs with the antigen, thereby reducing the immune response in the subject.
22. The method of claim 14 , wherein said reduction of the presentation of antigen on FDCs results in a reduction of the immune response in the subject.
23. The method of claim 22 , wherein the blocking agent is administered to the subject prior to the introduction of the antigen into the subject, such that the presentation of antigen on FDCs is reduced, thereby reducing the immune response in the subject.
24. The method of claim 22 , wherein the blocking agent is administered to the subject after association of the FDCs with the antigen, wherein said blocking agent disrupts the association of the FDCs with the antigen, thereby reducing the immune response in the subject.
25. The method of claim 15 , wherein said reduction of the presentation of antigen on FDCs results in a reduction of the immune response in the subject.
26. The method of claim 25 , wherein the blocking agent is administered to the subject prior to the introduction of the antigen into the subject, such that the presentation of antigen on FDCs is reduced, thereby reducing the immune response in the subject.
27. The method of claim 25 , wherein the blocking agent is administered to the subject after association of the FDCs with the antigen, and wherein said blocking agent disrupts the association of the FDCs with the antigen, thereby reducing the immune response in the subject.
28. The method of claim 1 , wherein the generation and maintenance of memory B cells in the subject is reduced.
29. The method of claim 2 , wherein the generation and maintenance of memory B cells in the subject is reduced.
30. The method of claim 5 , wherein the generation and maintenance of memory B cells in the subject is reduced.
31. The method of claim 6 , wherein the generation and maintenance of memory B cells in the subject is reduced.
32. The method according to claim 1 , wherein the LT-β-R blocking agent comprises an antibody directed against LT-β receptor.
33. The method according to claim 1 , wherein the LT-β-R blocking agent comprises an antibody directed against surface LT ligand.
34. The method of claim 5 , wherein the LT-β-R blocking agent comprises an antibody directed against LT-β receptor.
35. The method of claim 5 wherein, wherein the LT-β-R blocking agent comprises an antibody directed against surface LT ligand.